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Abstract 
Glanzmann’s thrombasthenia (GT) is a rare congenital bleeding disorder associated with 
decreased platelet aggregation due to qualitative/quantitative deficiencies of the fibrinogen receptor. 
Severe bleeding episodes and perioperative bleeding are typically managed with platelet transfusions, 
although patients can develop anti-platelet antibodies or experience clinical refractoriness. The GT 
Registry (GTR) was established to collect efficacy/safety data on hemostatic treatments for GT, including 
recombinant factor VIIa (rFVIIa). At the request of the United States Food and Drug Administration, 
three hematology experts evaluated platelet refractoriness, antibody status, and rFVIIa efficacy data on a 
case-by-case basis to support a potential indication for rFVIIa in GT. Adjudication included 195 patients 
with 810 events (619 severe bleeding episodes, 192 surgeries), and a consensus algorithm was developed 
to describe adjudicators’ coding of refractoriness and antibody status based on treatment patterns over 
time. Most rFVIIa-treated events were in patients without refractoriness or antibodies. Adjudicators rated 
most rFVIIa-treated bleeding episodes as successful (251/266, 94.4%; rFVIIa only, 101/109, 92.7%; 
rFVIIa ± platelets ± other agents, 150/157, 95.5%); efficacy was consistent in patients with platelet 
refractoriness ± antibodies (75/79, 94.9%), antibodies only (10/10, 100.0%), and neither/unknown 
(166/177, 93.8%). Adjudicators also rated most rFVIIa-treated surgeries as successful (159/160, 99.4%; 
rFVIIa only, 65/66, 98.5%; rFVIIa ± platelets ± other agents, 94/94, 100.0%); efficacy was consistent in 
patients with platelet refractoriness ± antibodies (69/70, 98.6%), antibodies only (24/24, 100.0%), and 
neither/unknown (66/66, 100.0%). Unblinding the adjudicators to investigator efficacy ratings changed 
few assessments. Doses of rFVIIa were narrowly distributed, regardless of other hemostatic agents used.  
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Introduction:  
Glanzmann’s thrombasthenia (GT) is a rare autosomal recessive bleeding disorder caused by a 
deficiency of, or an abnormality in the platelet membrane glycoproteins IIb or IIIa (GPIIb/IIIa) [1]. These 
glycoproteins bind fibrinogen to mediate platelet cross-linking, and therefore patients with GT exhibit 
reduced platelet aggregation responses and clinical bleeding. The severity of bleeding episodes in patients 
with GT varies and manifestation typically begins in childhood, with symptoms including primarily 
mucocutaneous bleeding, such as purpura, epistaxis, gingival bleeding, easy bruising, and ecchymoses [2, 
3]. Three classifications of GT have been established based on differences in GPIIb/IIIa levels; Type I, 
Type II, and Type III GT indicate GPIIb/IIIa levels of less than 5% of normal, 5-20% of normal, and with 
a qualitative defect in GPIIb/IIIa function, respectively. 
Treatment approaches towards managing bleeding in patients with GT generally vary with 
bleeding tendency [2, 4]. Whereas mild and moderate episodes can typically be controlled with 
compression, local hemostatic agents, and antifibrinolytic therapy, standard treatment for more severe 
bleeding events and for surgical interventions most often consists of platelet transfusions. However, 
platelet transfusions are associated with certain risks, including the potential transmission of blood-borne 
agents and occurrence of immunologic transfusion reactions [5]. The use of platelet therapy may also be 
limited by a short platelet shelf-life (5-7 days) and potentially low availability in some hospitals or blood 
banks. Additionally, performing platelet transfusions requires patient evaluation in a health care facility, 
and therefore early administration of platelets in the home setting is not feasible. Furthermore, following 
repeated platelet transfusions patients with GT may develop alloantibodies targeting GPIIb/IIIa or human 
lymphocyte antigen (HLA), and may experience clinical refractoriness to subsequent platelet treatment 
[2-4].  
An additional therapeutic option for managing severe bleeding in patients with GT is recombinant 
factor VIIa (rFVIIa), which has been used successfully to control bleeding episodes and peri-operative 
bleeding in patients with GT, often in combination with antifibrinolytic therapy [6-8]. The precise 
mechanism by which rFVIIa promotes hemostasis is unknown, but is thought to include an increased 
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activation of platelets, increased generation of thrombin, and increased deposition of fibrin, resulting in a 
stable and effective clot [9-11].  
Because of the rarity of GT and difficulties in enrolling sufficient numbers of patients for a 
randomized controlled trial, a prospective multinational GT Registry (GTR) was established to collect 
data regarding the efficacy and safety of hemostatic treatments for GT, including rFVIIa. The registry was 
initiated as a post-marketing surveillance commitment to the European Union’s Committee for Medicinal 
Products for Human Use, following approval by the European Medicines Agency of rFVIIa for the 
treatment of GT [12]. An external expert group monitored the registry and provided ongoing support of 
recruitment and analysis, including publication of primary data on the efficacy and safety of rFVIIa 
associated with specific patient events (bleeding episodes and surgeries) [13, 14]. Investigators found 
rFVIIa used alone to be effective in a majority of bleeding episodes (111 of 122; 91.0%) and surgical 
procedures (59 of 62; 95.2%).  
Following discussion with the United States Food and Drug Administration (FDA) regarding a 
potential new indication of GT for rFVIIa, an objective adjudication committee of US hematologists 
unaffiliated with the registry was assembled to evaluate rFVIIa efficacy, platelet refractoriness, and anti-
platelet antibody (anti-GPIIb/IIIa and anti-HLA) data from the GTR. Patient data were reviewed 
independently by the three adjudicators on a case-by-case basis in the context of all available information, 
including data from multiple events that occurred in each specific patient. Here we present a detailed 
methodology of the adjudication process and results. These data were used to support the FDA approval 
in July, 2014, of rFVIIa for patients with GT with refractoriness to platelet transfusions, with or without 
antibodies to platelets [15]. 
 
Methods: 
Study Population 
A detailed description of the GTR data collection process has been presented elsewhere [13, 14]. 
Briefly, the registry was a prospective, observational, multinational, Web-based platform that collected 
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safety and efficacy data regarding the use of systemic hemostatic treatments in patients with GT (see 
supplemental appendix for a list of data fields). Patients were eligible for participation in the GTR if they 
had a diagnosis of congenital GT and exhibited a normal platelet count and morphology [13, 14].  
Congenital GT was defined by having a lifelong bleeding tendency characterized by impaired or absent 
platelet aggregation, impaired clot retraction and prolonged bleeding time, or prolonged platelet function 
analyzer closure time; optional diagnostic criteria were quantitative or qualitative evaluation of GPIIb/IIIa 
receptors, including flow cytometry and identification of gene defects [13, 14]. Those with acquired 
platelet disorders, caused either by autoimmune disorders or medications, were excluded. All treatment 
decisions were based on local clinical practice. Patients were recruited between May 2007 and December 
2011, and were enrolled from a total of 45 sites representing 15 countries.  
The study was conducted in accordance with the Declaration of Helsinki and Guidelines for Good 
Pharmacoepidemiology Practices. Before data entry, each site obtained approval by any necessary 
Independent Ethics Committee of Institutional Review Board, and by any local regulatory authorities. 
Informed consent was obtained from all patients, or from parents or other legal guardians for patients not 
of age to provide informed consent. 
 
Investigator Reports 
The case report forms completed by investigators collected patient information specific to single 
hemostatic events (bleeding episodes and surgical procedures), including patient histories, treatment 
reports, and assessments of treatment effectiveness, platelet refractoriness, and the presence of anti-
platelet antibodies (HLA and/or anti-GPIIb/IIIa). Investigators entered information on refractoriness and 
antibody status at the time of each patient’s enrollment and whenever either status changed. Effectiveness 
was evaluated on a 4-point scale of effective (hemostasis achieved for 6 hours or more or bleeding 
stopped), partially effective (bleeding was mild or decreased substantially), ineffective (bleeding was 
excessive or unchanged/worsened), or not possible to evaluate. Case report forms allowed for but did not 
require the inclusion of narratives to support case descriptions, treatment, and results, which were 
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completed variably by the participating sites. Queries were sent to sites in cases of missing, inconsistent, 
or ambiguous information, and responses were added to the case report forms as necessary.  
 
Adjudication 
An in-person adjudication meeting was held from January 16-18, 2013, in which three 
adjudicators gathered to review data from each patient within the GTR on a case-by-case basis. Members 
of the adjudication committee were chosen from a list of 6 US experts proposed by Novo Nordisk and 
approved by the FDA based upon availability. The adjudicators individually performed 2 independent 
evaluations of platelet refractoriness, anti-platelet antibody status, and rFVIIa effectiveness for each 
treatment event; an initial assessment was performed without information regarding investigator 
evaluations (blinded review), and a subsequent assessment was performed following case report 
unblinding. For each patient being assessed for a particular bleeding or surgical treatment, data initially 
provided to the adjudicators included treatment regimen and outcome entered (ie, whether bleeding 
stopped and in what time frame); these were in addition to a summary list of patient demographics, initial 
platelet antibody/refractoriness status, and previous GT treatments. Investigator narratives on overall 
efficacy assessment for the particular episode was blinded initially and revealed only on the second fully 
unblinded review of the individual episodes. Each patient and their bleeding events were discussed twice 
by the committee, once following individual review of blinded data and once following review of 
unblinded data. Final assessments were considered the opinion of the adjudication committee if the same 
response was coded by 2 or 3 of the adjudicators; otherwise opinions were considered indeterminate (“no 
consensus”). During the blinded review only, adjudicators could after discussion come to a determination 
of insufficient information. 
Adjudicated refractoriness to platelet transfusions was determined by the 3 adjudicators with 
consideration of multiple criteria: 1) investigator-reported refractoriness at any time in the registry and/or 
the historical report of antibodies (GPIIb/IIIa or HLA if reported), 2) patterns of treatment consistent with 
unresponsiveness (eg, a switch in treatment regimen), and 3) perceived treatment responses, based on the 
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timing and extent of treatment compared to those of comparable episodes. Classification of patient 
refractoriness and antibody status was represented by four possible categories: refractory with antibodies, 
refractory with no antibodies, antibodies only, and none/unknown. All adjudicator assessments of 
refractoriness and antibody status presented here reflect final (unblinded) evaluations.  
As requested by the FDA, effectiveness assessments made by the adjudicators were classified on 
a 2-point scale of hemostasis achieved (success) or hemostasis not achieved (failure). 
 
Statistical Analysis 
 Data were summarized using descriptive statistics. Categorical variables are presented as numbers 
and percentages, and numerical variables as mean, median, and 5
th
, 25
th
, 75
th
, and 95
th
 percentiles.  
 
Results: 
The GTR contained data collected from 218 patients with GT who experienced a total of 1073 
events (870 bleeding episodes and 204 surgeries; one event was reported as both a bleeding episode and a 
surgery) (Fig. 1). Numbers of events considered in this FDA-requested adjudication plan differ slightly 
from those reported in previous analyses conducted by the GTR External Expert Panel because of 
differences in handling bleeding episodes; previous analyses had recategorized 2 episodes as surgeries, 
excluded 6 episodes as not appropriate for assessment, and excluded or collapsed 64 episodes as linked 
events [13, 14]. The adjudication analysis of platelet refractoriness and anti-platelet antibody status was 
performed on patients who experienced severe bleeding episodes or surgical procedures (excluding events 
characterized as easy bruising or subcutaneous bleeding), resulting in an adjudication population of 195 
patients with 810 treatment events (619 severe bleeding episodes and 192 surgical procedures). The 
adjudicated rFVIIa efficacy analysis was performed on patients in the adjudication population who 
received rFVIIa, resulting in a rFVIIa-treatment population of 131 patients who experienced a total of 266 
bleeding episodes (41% rFVIIa only; 59% rFVIIa + other hemostatic agents) and 160 surgical procedures 
(41% rFVIIa only; 59% rFVIIa + other hemostatic agents) including one surgical procedure where rFVIIa 
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was mentioned only in the free text narrative. Of the total of 10 emergency surgical procedures, 7 were 
treated with rFVIIa (4 of which were in patients with adjudicator-categorized antibodies or refractoriness) 
and 3 were treated with platelets (one of which was in a patient with adjudicator-categorized antibodies or 
refractoriness). Examples of rFVIIa-treated emergency procedures included endoscopy for upper GI 
bleeding, exploratory laparotomy and/or oophorectomy for ruptured ovarian cyst with bleeding (2 cases), 
interventions related to epistaxis (2 cases), and dilation and curettage following vaginal delivery for 
retained placental fragments. 
 
Adjudicated Platelet Refractoriness and History of Anti-Platelet Antibody Status 
Adjudicator assessments of platelet refractoriness and history of antibody status were reported for 
each individual treatment event, and incorporated a consideration of all available patient information, 
including data from any previous events included in the registry. Following the case-by-case review of 
refractoriness and antibody status, the adjudicators consolidated their assessment approaches into a 
consensus algorithm (Supplemental Fig. 1). This algorithm incorporates data regarding investigator 
assessments of refractoriness and antibody status, treatment approaches, and clinical responses, and 
describes the overall methodology developed to code refractoriness and antibody status.  
The adjudicator classifications of platelet refractoriness and anti-platelet antibody status were 
mostly consistent with those reported by the investigators (Table I). Adjudicator reclassifications 
included 58 out of 59 platelet-treated bleeding episodes (98.3%) and 3 out of 4 platelet-treated surgeries 
(75.0%) that were coded by the investigators as “refractory with antibodies” but reclassified by the 
adjudicators as “antibodies only.” This reclassification reflects a perceived inconsistency between the 
administration of platelets and a reported history of platelet refractory status, and modifies what appeared 
to be a different determination of platelet refractoriness by the investigators. The majority of these 
reclassified platelet-treated bleeding episodes (55 of 58) occurred in 2 children and were coded for 
effectiveness by the investigators as “effective” or “partially effective.” Adjudication also resulted in a 
reclassification of 24 out of 41 rFVIIa-treated bleeding episodes (58.5%) and 30 out of 45 rFVIIa-treated 
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surgical procedures (66.7%) that were coded by the investigators as “antibodies only” to “refractory with 
antibodies,” based on analysis of treatment patterns for similar bleed types over time. A majority of 
rFVIIa-treated bleeding episodes (177 of 266; 66.5%) and 66 of 160 (41.3%) of rFVIIa-treated surgical 
procedures occurred in patients without adjudicator-determined platelet refractoriness or anti-platelet 
antibodies.  
 
Adjudicated rFVIIa Efficacy 
The mean (median) age of the rFVIIa-treated population at first recorded event was 24.2 (21.5) 
years. Whereas the majority of rFVIIa-treated bleeding episodes occurred in patients aged 0 to 16 years 
(65%), most rFVIIa-treated surgical procedures occurred in patients older than 16 years (86%). A 
majority of patients were female (57%), and most were Caucasian (54%). The most common disease type 
was Type 1 (47%); 10% were Type II, 2% were Type III, and 41% were unknown. 
Bleeding Episodes 
The most frequently reported bleeding locations reported were epistaxis (44%), gum bleeding 
(18%), menorrhagia (14%), and oral bleeding associated with tooth or dental extraction (11%). The doses 
of rFVIIa administered per infusion were narrowly distributed (median [Q1, Q3], 90 [90, 95] µg/kg), and 
were similar between bleeding episodes treated with rFVIIa only (median [Q1, Q3], 90 [90, 90] µg/kg) 
and those treated with rFVIIa + other hemostatic agents (median [Q1, Q3], 90 [90, 100] µg/kg) 
(Supplemental Fig. 2A). The time interval between doses was also similar between bleeding episodes 
treated with rFVIIa only (median [Q1, Q3], 3.0 [2.0, 4.0] hours) and those treated with rFVIIa + other 
hemostatic agents (median [Q1, Q3], 3.0 [2.0, 6.0] hours) (Supplemental Fig. 2B), although the number 
of doses administered per event was greater for episodes treated with rFVIIa + other hemostatic agents 
(median [Q1, Q3], 3.0 [1.0, 6.0]) than for those treated with rFVIIa only (median [Q1, Q3], 2.0 [1.0, 3.0]) 
(Supplemental Fig. 2C). This dosing data served as the basis for the indicated dosing for GT in the 
United States. 
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Overall, adjudicators rated most rFVIIa-treated bleeding episodes as successful (94.4%); few 
episodes were reported as a treatment failure (1.5%) (Table II). Rates of treatment success were similar 
between bleeding episodes treated with rFVIIa only (92.7%) and those treated with rFVIIa + other 
hemostatic agents (95.5%), and were similar between all adjudicator-assessed antibody/refractoriness 
categories (93.8% to 100.0%). Detailed information regarding dosing and efficacy by type of bleeding 
episode is shown in Supplemental Table I. 
Surgical Procedures 
A majority of the surgical procedures were reported as elective (92%); 4% were reported as 
emergencies and 4% were unspecified. The most frequent types of surgical procedures were dental (66%), 
endoscopy (8%), and nasal (5%). The doses of rFVIIa administered per infusion were similar between 
surgical procedures treated with rFVIIa only (median [Q1, Q3], 90 [90, 115] µg/kg) and those treated 
with rFVIIa + other hemostatic agents (median [Q1, Q3], 92 [90, 135] µg/kg) (Supplemental Fig. 3A); 
the time interval between doses was also similar between these surgical groups (median [Q1, Q3], 2.0 
[2.0, 3.0] hours and 3.0 [2.0, 5.0] hours, respectively) (Supplemental Fig. 3B). Numbers of doses per 
admission were greater for episodes treated with rFVIIa + other hemostatic agents (median [Q1, Q3], 3.0 
[2.0, 5.0]) than for those treated with rFVIIa only (median [Q1, Q3], 2.5 [2.0, 3.0]) (Supplemental Fig. 
3C), and were greater for major surgeries than for minor surgeries (median [Q1, Q3], 11.0 [3.0, 21.0] and 
2.5 [2.0, 3.0], respectively). This dosing data served as the basis for the indicated dosing for GT in the 
United States. 
Overall, adjudicators rated most rFVIIa-treated surgical procedures as successful (99.4%)  
(Table III). Rates of treatment success were similar between bleeding episodes treated with rFVIIa only 
(98.5%) and those treated with rFVIIa + other hemostatic agents (100.0%), and were similar between all 
adjudicator-assessed antibody/refractoriness categories (98.6% to 100.0%). Detailed information 
regarding dosing and efficacy by type of surgical procedure is shown in Supplemental Table I. 
Investigator-Reported vs. Adjudicator-Assessed Effectiveness 
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Blinded adjudicator assessments of efficacy were largely consistent with investigator 
effectiveness ratings (Supplemental Table II). Of the 255 bleeding episodes and 155 surgical procedures 
that were rated by investigators as effective or partially effective, 240 bleeding episodes (94.1%) and 154 
surgeries (99.4%) were rated by the adjudicators as successful. Twelve bleeding episodes and 1 surgical 
procedure that were rated by the investigators as effective or partially effective were classified by the 
adjudicators as insufficient data. Of the 5 bleeding episodes and 3 surgical procedures that were rated by 
the investigators as ineffective, 4 bleeding episodes (80.0%) and 3 surgical procedures (100.0%) were 
classified by the adjudicators as successful; all 8 of these events were in cases where rFVIIa was used in 
conjunction with other hemostatic agents and/or platelets.  
The unblinding of adjudicators to investigator effectiveness ratings had minimal effect on 
adjudicator assessments. Seven bleeding episodes that were rated as insufficient data in adjudicators’ 
blinded assessments were reclassified after un-blinding; one episode was reclassified to treatment success, 
one bleeding episode was reclassified to treatment failure, and 5 episodes were reclassified with no 
consensus. No surgical procedures were reclassified following unblinded review.  
 
Discussion: 
Expert adjudication of the GTR data provided an objective assessment of individual patient case 
reports and a consistent approach towards determining platelet refractoriness, antibody status, and 
treatment effectiveness. An important goal of the adjudication process was to reduce biases caused by 
variability in investigator assessments and incompleteness of data; adjudicators benefitted from an 
objective perspective in which patient data could be reviewed in the context of any additional events 
included in the registry, and assessments were based on patterns of treatment over time. These methods 
provide a unique way to examine observational data beyond descriptive statistics to learn more about the 
underlying disease state and treatment variability, and may provide a model for independent review of 
similar data sets.  
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The GTR is the largest observational study on GT and few previous studies have investigated 
rFVIIa efficacy data in this patient population, although the adjudicated rFVIIa efficacy findings are 
consistent with reports from these previous studies. Results of an international survey demonstrated high 
rates of physician-reported rFVIIa efficacy in the treatment of bleeding episodes (77 of 103 [74.8%]; 
although 8 bleeding episodes occurred within 48 hours after successful treatment, giving an overall 
efficacy rate of 69/103 [67.0%]) and in surgical/invasive procedures (29 of 31; 93.5%) in patients with 
GT [7]. Additionally, an open-label Iranian study in patients with GT reported a “good” or “partial” 
response to rFVIIa in 26 of 28 bleeding episodes (92.9%) [6]. Results of multiple case reports in patients 
with GT also presented rFVIIa efficacy data, and demonstrated an overall rFVIIa response rate of 25 of 
36 bleeding episodes (69.4%) and 27 of 28 surgeries (96.4%) [8].  
A notable finding of this analysis was the high use of rFVIIa in patients classified by the 
investigators as having neither platelet refractoriness nor antibodies, despite the indication in the 
European label for patients with GT with antibodies to GPIIb/IIIa and/or HLA and with past or present 
refractoriness to platelet transfusions [8]. This pattern of use may reflect efforts by physicians to avoid 
platelet exposure and therefore reduce the potential for patients to develop refractoriness, or in some cases 
a potential unavailability of platelets as an immediate treatment option or a greater convenience of rFVIIa 
compared to platelet transfusions.  
Safety data from the GTR have been previously reported, and indicate a favorable safety profile 
of rFVIIa in patients with GT [13, 14, 16]. The only serious adverse event probably or possibly related to 
rFVIIa was a deep vein thrombosis reported in a 25-year-old female receiving rFVIIa, platelets, and 
packed red blood cells 8 days after an emergency laparotomy for an ovarian cyst with hematoma and 
ureteral compression [14]. 
The GTR results have been presented in 2 previous reports of investigator-reported data based 
upon the analysis by the GTR External Expert Panel following reclassification of certain episodes [13, 
14], in addition to the current report of adjudicated data based upon the FDA-approved adjudication plan. 
Minor differences in methodologies resulted in slightly different reports of patient numbers and treatment 
Page 13 of 30
John Wiley & Sons
American Journal of Hematology
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
 
14 
 
events between these two sets of analyses and the primary report of post-marketing surveillance data 
submitted to European Medicines Authority on an annual basis and following closure of the registry. 
Unlike previous published reports, the current analysis excluded events characterized by 
subcutaneous/easy bruising and those treated only with antifibrinolytics, which were considered to not 
meet criteria agreed upon for severe bleeds requiring systemic hemostatic therapy. Prior publications are 
also based on an independent analysis of raw data files, and reflect collapsing of linked admissions to 
index events, exclusion of non-bleeding events, and recategorization of 2 bleeding episodes as surgical 
events (see figure 1 in [13]). While the multiple records for single admissions were easily identified based 
upon the “notes” provided in the CRFs reviewed and questioned by the adjudicators, the adjudication plan 
did not allow for consolidation of multiple records where each had an investigator reported efficacy 
assessment; in contrast, the GTR External Expert Panel was able to consolidate those records with a 
single efficacy assessment. 
An important limitation of the adjudication analysis presented here is the limited and variable 
amount of patient data provided by the investigators. The underlying raw data from EMA reporting was 
analyzed by the adjudicators, however, because the GTR had closed at the time of the analysis, 
adjudicators were limited to data and case narratives that had been submitted by the investigators, and had 
no opportunities to query the data. Additionally, although data on platelet refractoriness and antibody 
status could be reported by investigators during each event, these fields were not required in the registry. 
Adjudicators were also directed not to merge or consolidate treatment events, even if the case report 
forms clearly indicated that subsequent events had resulted from a single bleed, which contributed to 
some of the “insufficient data” or “no consensus” findings. Coding for treatment regimen could be 
modified based upon product mention in open text narratives (eg, 1 of 160 rFVIIa-treated surgeries where 
rFVIIa was noted only in narrative), and post-bleed transfusions without hemostatic treatment could be 
excluded. Variable definitions and scales for the evaluation of efficacy, as well as variable time periods 
after bleeding for investigator assessments, relative to the entire treatment regimen documented, may also 
limit comparisons of investigator and adjudicator-coded efficacy. For example, adjudicators’ 
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consideration of the entire treatment, including rFVIIa dosing/pattern and treatment sequence (first-line 
vs. second-line or salvage rFVIIa, when platelets or other hemostatic agents were used relative to efficacy 
assessment), likely contributed to evaluation as successful 7 of 8 bleeding episodes/surgeries that 
investigators reported at the time of assessment to be ineffective. Another notable aspect of the 
adjudication analysis is the sponsorship by Novo Nordisk Inc; adjudicators may therefore be perceived as 
lacking complete independence in their assessments.  
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Table I. Comparison of Investigator-Reported and Adjudicator-Categorized Refractoriness 
and Antibody Status in Bleeding Episodes and Surgical Procedures  
 
 Adjudicator-categorized refractory/antibody status, n (%) 
 
Refractory + 
antibodies 
Refractory - 
antibodies 
Antibodies 
onlya 
None/ 
unknown Total 
Bleeding Episodes 
 Any rFVIIa-treated bleeding episode (n=266) 
Investigator-
reported 
status 
Refractory + 
antibodies 
18 (78.3) - 4 (17.4) 1 (4.3) 23 
Refractory - 
antibodies 
- 33 (82.5) - 7 (17.5) 40 
Antibodies 
onlya 
24 (58.5) - 6 (14.6) 11 (26.8) 41 
None/unknown 4 (2.5) - - 158 (97.5) 162 
 Any platelet-treated bleeding episode (n=298) 
Investigator-
reported status 
Refractory + 
antibodies 
1 (1.7) - 58 (98.3) - 
59 
Refractory - 
antibodies 
- - 1 (14.3) 6 (85.7) 
7 
Antibodies 
onlya 
- - 27 (58.7) 19 (41.3) 
46 
None/unknown - - - 186 (100.0) 186 
Surgical Procedures 
  Any rFVIIa-treated surgical procedure (n=160) 
Investigator-
reported status 
Refractory + 
antibodies 
28 (71.8) - 11 (28.2) - 
39 
Refractory - 
antibodies 
- 12 (92.3) - 1 (7.7) 
13 
Antibodies 
onlya 
30 (66.7) - 13 (28.9) 2 (4.4) 
45 
None/unknown - - - 63 (100.0) 63 
  Any platelet-treated surgical procedure (n=32) 
Investigator-
reported status 
Refractory + 
antibodies 
1 (25.0) - 3 (75.0) - 
4 
Refractory - 
antibodies 
- - - - 
0 
Antibodies 
onlya 
1 (9.1) - 8 (72.7) 2 (18.2) 
11 
None/unknown - - - 17 (100.0) 17 
a
Refers to antibody status specified and refractory none or unknown. 
Shaded boxes reflect identical investigator and adjudicator ratings. 
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Table II. Adjudicator Evaluation of Efficacy – Bleeding Episodes 
 
No. of 
Patients
e
 
No. of 
Episodes 
Success 
n (%) 
Failure 
n (%) 
Insufficient 
Data  
n (%) 
No 
Consensus 
n (%) 
All rFVIIa
a
 92 266 251 (94.4) 4 (1.5) 6 (2.3) 5 (1.9) 
By treatment regimen 
rFVIIa only 
rFVIIa ± platelets ± other hemostatic agents 
 
44 
69 
 
109 
157 
 
101 (92.7) 
150 (95.5) 
 
2 (1.8) 
2 (1.3) 
 
4 (3.7) 
2 (1.3) 
 
2 (1.8) 
3 (1.9) 
By antibody/refractory group 
Refractoriness ± platelet-specific antibodies
b,c
 
Platelet-specific antibodies
b,c
 
Neither or unknown
c,d
 
 
31 
8 
57 
 
79 
10 
177 
 
75 (94.9) 
10 (100.0) 
166 (93.8) 
 
2 (2.5) 
0 
2 (1.1) 
 
2 (2.5) 
0 
4 (2.3) 
 
0 
NA 
5 (2.8) 
a
All treatment regimens that included treatment with rFVIIa. 
b
Includes GPIIb/IIIa, HLA, and unspecified platelet-specific antibodies. 
c
Treatment was rFVIIa only for 26/79 episodes with refractoriness with or without antibodies, 2/10 episodes with platelet-specific antibodies only, and 81/177 
episodes with neither or unknown. The remainder received rFVIIa with platelets and/or antifibrinolytic agents. 
d
Assumes no platelet-specific antibodies or refractoriness reported or antibody and refractory status unknown. 
e
Patient numbers are not additive. Patients may have episodes with different treatment regimens and have more than one antibody/refractory status. 
 
Page 19 of 30
John Wiley & Sons
American Journal of Hematology
57
58
59
60
This article is protected by copyright. All rights reserved.
Ac
c
e
p
t
e
d
 
A
r
t
i
c
l
e
Table III. Adjudicator Evaluation of Efficacy – Surgical Procedures 
 
No. of Patients
e
 No. of Procedures 
Success 
n (%) 
Insufficient Data
f
 
n (%) 
All rFVIIa
a
 77 160 159 (99.4) 1 (0.6) 
By treatment regimen 
rFVIIa only 
rFVIIa ± platelets ± other hemostatic agents 
 
35 
57 
 
66 
94 
 
65 (98.5) 
94 (100.0) 
 
1 (1.5) 
0 
By antibody/refractory group 
Refractoriness ± platelet-specific antibodies
b,c
 
Platelet-specific antibodies
b,c
 
Neither or unknown
b,d
 
 
33 
11 
36 
 
70 
24 
66 
 
69 (98.6) 
24 (100.0) 
66 (100.0) 
 
1 (1.4) 
0 
0 
a
All treatment regimens that included treatment with rFVIIa. 
b
Includes GPIIb/IIIa, HLA, and unspecified platelet-specific antibodies. 
c
Treatment was rFVIIa only for 22/70 episodes with refractoriness with or without antibodies, 13/24 episodes with platelet-specific antibodies only, and 31/66 
episodes with neither or unknown. The remainder received rFVIIa with platelets and/or antifibrinolytic agents. 
d
Assumes no platelet-specific antibodies or refractoriness reported or antibody and refractory status unknown. 
e
Patient numbers are not additive. Patients may have episodes with different treatment regimens and have more than one antibody/refractory status. 
f
No reports of failure or lack of consensus was reported. 
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Figure 1  
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Supplemental Table I. rFVIIa Dosing and Efficacy by Type of Bleeding Episode or Surgery 
 rFVIIa Dosing rFVIIa Efficacy 
Number of 
Episodes or 
Procedures 
Dose per Infusion 
(µg/kg), 
Median (IQR) 
Total Dose per Episode 
or Procedure (µg/kg), 
Median (IQR) 
Number of Doses per 
Episode or Procedure,  
Median (IQR) 
Treatment Duration 
(Hours), 
Median (IQR) 
Number of 
Episodes or 
Procedures 
Efficacy, 
% 
Bleeding Type 
Epistaxis 
Menorrhagia 
Gum bleeding 
Teeth or dental 
Gastrointestinal 
Other 
Unknown 
 
103 
36 
27 
26 
22 
38 
7 
 
90 (90-90) 
90 (90-90) 
90 (90-100) 
90 (86-96) 
92 (90-107) 
90 (90-95) 
107 (107-120) 
 
180 (90-290) 
270 (180-497) 
180 (90-286) 
285 (90-574) 
270 (180-540) 
270 (90-540) 
130 (90-600) 
 
2 (1.0-3.0) 
3 (2.0-4.5) 
2 (1.0-3.0) 
3 (1.0-6.0) 
3 (2.0-6.0) 
3 (1.0-6.0) 
1 (1.0-5.0) 
 
5.0 (4.0-25.5) 
5.0 (4.0-36.0) 
4.0 (3.0-15.0) 
22.5 (8.0-28.5) 
20.5 (3.0-41.0) 
25.8 (6.0-44.0) 
8.0 (3.0-32.0) 
 
106 
36 
28 
24 
23 
40 
7 
 
95.3 
97.2 
92.9 
96.2 
82.6 
97.5 
85.7 
Surgery Type 
Major 
Minor 
 
25 
132 
 
90 (90-92) 
100 (90-140) 
 
990 (270-2167) 
270 (180-428) 
 
11.0 (3.0-21.0) 
2.5 (2.0-3.0) 
 
48.5 (9.0-97.5) 
4.5 (3.0-8.0) 
 
26 
134 
 
96.2 
100.0 
IQR, interquartile range. 
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Supplemental Table II. Comparison of Investigator-Reported and Blinded/Unblinded Adjudicator 
Effectiveness Evaluations – rFVIIa 
 
Investigator Effectiveness Rating 
Effective
a
 
Partially 
Effective
b
 Ineffective
c
 
Not 
Evaluated Total 
rFVIIa-Treated Bleeding Episodes (n=266) 
Blinded adjudicator 
effectiveness rating 
Success, n (%) 
Failure, n (%) 
Insufficient data, n (%) 
No consensus, n (%) 
 
 
197 (74.1) 
0 
7 (2.6) 
0 
 
 
43 (16.2) 
3 (1.1) 
5 (1.9) 
0 
 
 
4 (1.5) 
0 
1 (0.4) 
0 
 
 
6 (2.3) 
0 
0 
0 
 
 
250 (94.0) 
3 (1.1) 
13 (4.9) 
0 
Unblinded adjudicator 
effectiveness rating 
Success, n (%) 
Failure, n (%) 
Insufficient data, n (%) 
No consensus, n (%) 
 
 
198 (74.4) 
0 
3 (1.1) 
3 (1.1) 
 
 
43 (16.2) 
3 (1.1) 
3 (1.1) 
2 (0.8) 
 
 
4 (1.5) 
1 (0.4) 
0 
0 
 
 
6 (2.3) 
0 
0 
0 
 
 
251 (94.4) 
4 (1.5) 
6 (2.3) 
5 (1.9) 
rFVIIa-Treated Surgical Procedures (n=160) 
Blinded adjudicator 
effectiveness rating 
Success, n (%) 
Failure, n (%) 
Insufficient data, n (%) 
No consensus, n (%) 
 
 
140 (87.5) 
0 
1 (0.6) 
0 
 
 
14 (8.8) 
0 
0 
0 
 
 
3 (1.9) 
0 
0 
0 
 
 
2 (1.3) 
0 
0 
0 
 
 
159 (99.4) 
0 
1 (0.6) 
0 
Unblinded adjudicator 
effectiveness rating 
Success, n (%) 
Failure, n (%) 
Insufficient data, n (%) 
No consensus, n (%) 
 
 
140 (87.5) 
0 
1 (0.6) 
0 
 
 
14 (8.8) 
0 
0 
0 
 
 
3 (1.9) 
0 
0 
0 
 
 
2 (1.3) 
0 
0 
0 
 
 
159 (99.4) 
0 
1 (0.6) 
0 
a
Effective: bleeding episode stopped or hemostasis achieved for 6 hours or more; normal hemostasis achieved 
during surgical procedure.  
b
Partially effective: bleeding during episode decreased substantially but continued; mild bleeding tendency during 
surgical procedure. 
c
Ineffective: bleeding during episode unchanged or worsened; excessive bleeding tendency during surgical 
procedure. 
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Supplemental Figure 1. aAntibodies that were indicative of anti-platelet antibodies (e.g. anti-GP IIb/IIIa, 
anti-HLA, but excluding those clearly not anti-platelet such as anti-coombs, anti-D, anti- E). OH = other 
hemostatic agents (excluding rFVIIa and platelets).  
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Supplemental Figure 2A. Indicated dosing: 90µg/kg (Panel A, dashed line) every 2-6 hours (Panel B, gray 
shading) until hemostasis is achieved.  
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Supplemental Figure 2B. Indicated dosing: 90µg/kg (Panel A, dashed line) every 2-6 hours (Panel B, gray 
shading) until hemostasis is achieved.  
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Supplemental Figure 2C. Indicated dosing: 90µg/kg (Panel A, dashed line) every 2-6 hours (Panel B, gray 
shading) until hemostasis is achieved.  
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Supplemental Figure 3A. Indicated dosing: 90µg/kg (Panel A, dashed line) immediately before surgery and 
every 2 hours for the duration of the procedure; 90µg/kg every 2-6 hours (Panel B, gray shading) to 
prevent post-operative bleeding.  
 
155x86mm (150 x 150 DPI)  
Page 28 of 30
John Wiley & Sons
American Journal of Hematology
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
  
 
 
Supplemental Figure 3B. Indicated dosing: 90µg/kg (Panel A, dashed line) immediately before surgery and 
every 2 hours for the duration of the procedure; 90µg/kg every 2-6 hours (Panel B, gray shading) to 
prevent post-operative bleeding.  
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Supplemental Figure 3C. Indicated dosing: 90µg/kg (Panel A, dashed line) immediately before surgery and 
every 2 hours for the duration of the procedure; 90µg/kg every 2-6 hours (Panel B, gray shading) to 
prevent post-operative bleeding.  
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